Introduction {#s0005}
============

Neuroendocrine tumors (NETs) occupy a distinctive group of tumors for their unique biological characteristics and various original sites [@bb0005]. Lung cancer is one kind of frequent malignant tumor that possesses of the top morbidity and mortality compared with other tumors in the world. Pulmonary neuroendocrine tumors (NETs) account for nearly 25% of all types of lung cancers [@bb0010]. According to the 2015 WHO classification guideline, pulmonary NETs were categorized into typical carcinoid (TC), atypical carcinoid (AC), large cell neuroendocrine carcinoma (LCNEC) and small cell lung carcinoma (SCLC). According to the differentiation of tumors, TC and AC were classified into the low- to intermediate-grade pulmonary NETs, while LCNEC and SCLC were classified into the high-grade pulmonary NETs [@bb0015].

Clinically, no specific chemotherapy regimen has been proved effective for LCNEC. Therefore, LCNEC patients generally receive chemotherapy similar to non-small cell lung carcinoma (NSCLC) in advanced stage. In contrast, SCLC patients receive specific chemotherapy regimens at any stage [@bb0020], [@bb0025]. However, in clinical practice, we discovered that LCNEC might share some similarity with SCLC, other than TC or AC, in morphology, immunoprofile and poor prognosis.

The p53 protein, as a tumor suppressor gene, predictive of sensitivity to platinum, was reported to be commonly functional inactivated in the high-grade NETs compared to the low- to intermediate-grade NETs [@bb0030], [@bb0035]. In addition, in gastrointestinal and pancreatic neuroendocrine tumors, p53 expression was also up-regulated in the high-grade NETs compared with the low- to intermediate-grade ones [@bb0040]. Besides, CD117 as a transmembrane tyrosine kinase receptor (TKR) was reported to be overexpressed in most of the high-grade NETs, which suggested a potential therapy of Imatinib [@bb0040], [@bb0045]. Moreover, somatostatin receptor 2A/5 (SSR2A/5) and phosphatase and tensin homolog (PTEN) expression levels, which were predictive of sensitivity to somatostatin analog and mammalian target of rapamycin (mTOR) inhibitor treatment, respectively, were reported significantly decreased with tumor grade progression, regardless of the site of tumors [@bb0050], [@bb0055]. Therefore, we wondered whether some similar phenomena in the expression of these markers could be discovered in pulmonary NETs.

In this study, we retrospectively retrieved 117 cases of pulmonary NETs in the Department of Thoracic Surgery, Zhongshan Hospital, which were subdivided into TC (10), AC (13), LCNEC (59) and SCLC (35) according to the 2015 WHO classification guideline. Survival curves were drawn and analyzed by the Kaplan--Meier product limit estimator. Immunohistochemical studies were applied to detect p53, CD117, SSR2A, SSR5 and PTEN expressional level in pulmonary NETs. Taking together the data above with statistical analysis, we tried to explore whether LCNEC and SCLC share some similarity in some aspects, which might guide novel therapy for pulmonary NETs.

Materials and Methods {#s0010}
=====================

Case Selection And Follow-Up {#s0015}
----------------------------

The flow chart of the case selection was shown in [Figure 1](#f0005){ref-type="fig"}. From 2005 to 2016, a total of 154 patients who received complete surgical removal of the primary lung tumor and were diagnosed with pulmonary NETs in the Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, China, were selected for the study. Each pathological section was reviewed by three experienced pathologists, making the final diagnosis according to the 2015 WHO classification guideline. To eliminate the interference factors, we excluded those patients that had history of other malignancy, neoadjuvant therapy or were pathological diagnosed as "mixed carcinoma". After exclusion, 117 patients were eligible for the study and subdivided as follows: 10 TCs, 13 ACs, 59 LCNECs and 35 SCLCs. It is worth mentioning that all the patients were selected only in the Department of Thoracic surgery, not including those patients that in extensive stage with distant metastasis, especially SCLC patients, which led to the little proportion of SCLC cases enrolled in this study. Each patient has been informed of the research purpose and procedure in details, and agreed with the subject. This study was approved by the ethics committee on human research of Zhongshan Hospital.Figure 1The flow chart of the case selection.Figure 1

In the analysis of survival, 84 patients who had detailed 5-year follow-up records were selected for overall survival (OS). For the follow-up, each patient was required to take chest CT, abdominal ultrasonography and serum tumor markers every 3-month during the first year after surgery. Thereafter, patients were followed-up twice a year. Brain MRI and full body bone scan were applied at every anniversary follow-up of the surgery. Patients\' data was collected in details, including age, sex, smoking status, tumor site, tumor size, tumor pathology, lymph node metastasis, TNM stage (according to American Joint Committee on Cancer (AJCC), eighth edition) [@bb0060], etc. Patients whose pathology were classified as SCLC or proved N1 lymph nodes metastasis received postoperative adjuvant chemotherapy. SCLC patients received EP regimen (etoposide and platinum), and carcinoid and LCNEC patients received TP regimen (paclitaxel and platinum). Those patients with N2 lymph nodes metastasis were received postoperative adjuvant radiotherapy.

Immunohistochemical Staining (IHC) {#s0020}
----------------------------------

IHC was performed as previously described [@bb0065]. Three experienced pathologists, who were unknown of the content and purpose of the study, were invited to score the IHC results. The scoring standards were listed as follows. For SSR2A and SSR5 expression, we performed semi-quantitative scoring based on both subcellular localization and the extent of staining. The scoring system was as follow: 0 (absence of immunoreactivity); 1 (pure cytoplasmic immunoreactivity); 2 (≤50% membranous immunoreactive cells); or 3 (\>50% membranous immunoreactive cells). Scores 0 and 1 were considered as negative, while scores 2 and 3 were considered as positive [@bb0070].

PTEN expression was evaluated on a semi-quantitative scale according to both the extent (score, 0--3 for positive cells, \<5, 5--40, 40--70, and \>70%, respectively) and the intensity (score, 0--3 for "-", "+", "++", and "+++", respectively) of staining. Multiply the score of the degree and intensity, cases with a score 0 were considered as negative, 1--4 were considered as low expression, and score of 6 and 9 were considered as high expression [@bb0075].

The p53 expression was considered as positive if the percentage of immunoreactions was observed in \>20% of tumor cells, while the rest were considered as negative [@bb0080].

CD117 expression was classified as follows: positivity of CD117 was defined when 1% or more tumor cell membranes were reactive, and the negative group was defined as absent expression or cytoplasmic expression of CD117 [@bb0085].

Statistical Analysis {#s0025}
--------------------

Statistical analysis was performed with the SPSS 17.0 software program. The Kaplan--Meier estimator was employed to draw OS curves. Correlation of variables were evaluated by the χ^2^ test, Fisher exact test, or and Spearman coefficients test, as appropriate, to analyze the difference between each subgroup. OS was defined as the time elapsed from the date of surgery to death. Two-tailed test results were considered significant at *P* \< .05.

Results {#s0030}
=======

LCNEC Shared Similarity With SCLC, Not Carcinoid, in Clinicopathology Features {#s0035}
------------------------------------------------------------------------------

As shown in [Table 1](#t0005){ref-type="table"}, we gathered related clinicopathologic features, including sex, age, smoking status, tumor site, tumor size, lymph node metastasis, TNM stage. Through statistical analysis, we could conclude that, compared with carcinoid (TC and AC), the LCNEC patients were older (mean age, 59.6 ± 9.5 vs. 48.1 ± 13.1 y, *P* = .007), and more commonly happened in male (83.1% vs. 52.2%, *P* = .004) and in advanced stage (stage II and above: 57.6% vs. 34.8%, *P* = .063). Smoking status, tumor site, tumor size and lymph node metastasis showed no significant difference between two subgroups. Notably, lymph node metastasis happened most frequently in SCLCs (48.6%), followed by LCNECs (37.3%) and least in Carcinoids (26.1%).Table 1The Analysis of the Associations Between Pulmonary NETs Subgroups and Clinicopathologic Features.Table 1Clinicalopathologic FeaturesCarcinoidLCNECSCLCAll 3 TypesCarcinoid vs. LCNECLCNEC vs. SCLCLow to Intermediate vs. High GradeNSCLC vs. SCLC(n = 23)(n = 59)(n = 35)*P* value*P* value*P* value*P* value*P* valueAge ≤55 years141710**.015.007**.980**.004**.338 \>55 years94225Sex Male124931**.002.004**.467**.001**.087 Female11104Smoking status Never/unknown163022.241.125.258.215.497 Former/current72913Tumor site Left72516.490.319.752.249.501 Right163419Tumor size ≤3 cm163118.319.161.917.131.557 \>3 cm72817Lymph node metastasis No173718.219.337.283.174.142 Yes62217TNM stage(8th) IA1-IB152516.169.063.752.063.761 IIA-IIIC83419[^2]

Then, we re-classified LCNEC and SCLC into the high-grade subgroup to compare them with the low- to intermediate-grade subgroup (carcinoid). The data showed that older age (mean age, 60.5 ± 9.1 vs. 48.1 ± 13.1 y, *P* = .004), male patients (85.1% vs. 52.2%, *P* = .001) and advanced stage (stage II and above: 54.3% vs. 34.8%, *P* = .063) were more common in the high-grade subgroup than those in the low- to intermediate-grade subgroup, which was consistent with the comparison between LCNEC and carcinoid. However, no significant difference was found in the comparison between LCNEC and SCLC. Furthermore, we combined carcinoid and LCNEC into NSCLC, and found that no significant difference existed in the comparison between NSCLC and SCLC.

LCNEC And SCLC Suffered Poorer Prognosis Than Carcinoid {#s0040}
-------------------------------------------------------

In survival analysis, we investigated the 5-year OS difference among carcinoid, LCNEC and SCLC. Up to 84 patients who received surgery before 2012, were enrolled in the analysis. The 5-year OS for the carcinoids, LCNECs, and SCLCs were 70.0%, 59.1%, and 32.1%, respectively (*P* = .036) ([Figure 2](#f0010){ref-type="fig"}*A* and [Table 2](#t0010){ref-type="table"}). The data showed that the prognosis of LCNEC was poorer than that of carcinoid, but better than that of SCLC.Figure 2The 5-year survival curves of the enrolled pulmonary NETs patients, obtained by Kaplan--Meier product limit estimator, were compared among different subtypes (A), TNM staging 7th edition (B) and TNM staging 8th edition (C).Figure 2Table 2The Analysis of Overall Survival Rate Between Pulmonary NETs SubgroupsTable 2Tumor TypeNo.Median Survival5-year OS(Months)(%)Carcinoid16NR70.0LCNEC40NR59.1SCLC283532.1[^3]

Currently, although there existed distinctive TNM stage for SCLC, no distinctive TNM stage for pulmonary NET has been released. For the reason that SCLC patients enrolled in this study were all in limited stage, we tried to apply 7th and 8th editions of the AJCC TNM stage for all these pulmonary NETs patients and to compare the prognostic value between these two editions. As shown in [Figure 2](#f0010){ref-type="fig"}, *B* and *C*, both 7th and 8th editions showed distinguished difference between carcinoids, LCNECs, and SCLCs (*P* = .000). To analyze the survival curve further, we figured out that in the 7th edition, the SCLC curve crossed the LCNEC curve during the first year after surgery, while in the 8th edition, no cross appeared among pulmonary NETs, which indicated that TNM 8th edition was superior in predicting the prognosis, compared with the TNM 7th edition in pulmonary NETs.

LCNEC Possessed Parallel Shifted Expression of Neuroendocrine-Related Markers With SCLC, Not Carcinoid {#s0045}
------------------------------------------------------------------------------------------------------

To explore the immunoprofile of neuroendocrine-related markers, we performed IHC to detect p53, CD117, SSR2A, SSR5 and PTEN expression in pulmonary NETs ([Figure 3](#f0015){ref-type="fig"}, [Figure 4](#f0020){ref-type="fig"}, [Figure 5](#f0025){ref-type="fig"}, [Figure 6](#f0030){ref-type="fig"}, [Figure 7](#f0035){ref-type="fig"}). As shown in [Table 3](#t0015){ref-type="table"}, p53 and CD117 expression was significantly higher in LCNECs than those in carcinoids (p53-positive: 67.8% vs. 34.8%, *P* = .006; CD117-positive: 39.0% vs. 0%, *P* = .000). Especially, all carcinoids showed negative CD117 expression. Conversely, both SSR2A/SSR5 expression scores and PTEN immunoreactivity levels were significantly lower in LCNECs than those in carcinoids (SSR2A-positive, 33.9% vs. 65.2%, *P* = .010; SSR5-positive, 6.8% vs. 30.4%, *P* = .005; PTEN-cytoplasm, 57.4% vs. 82.6%, *P* = .037).Figure 3P53 expression. Negative: complete absent or ≤ 20% tumor cells expression. (A) 5% expression of tumor cells; (B) 10% expression of tumor cells.Positive: \>20% tumor cells expression. (C) 60% expression of tumor cells; (D) 100% expression of tumor cellsFigure 3Figure 4CD117 expression. Negative: complete absent or cytoplasmic expression. (A) absent expression of tumor cells; (B) cytoplasmic expression of tumor cells.Positive: ≥1% tumor cells membranes expression. (C) 40% expression of tumor cell membranes; (D) 100% expression of tumor cell membranes.Figure 4Figure 5SSR2A expression. Negative: scores 0 and 1. (A) score 0: absent expression of tumor cells; (B) score 1: cytoplasmic expression of tumor cells. Positive: scores 2 and 3. (C) score 2: ≤50% expression of tumor cell membranes; (D) score 3: \>50% expression of tumor cell membranes.Figure 5Figure 6SSR5 expression. Negative: scores 0 and 1. (A) score 0: absent expression of tumor cells; (B) score 1: cytoplasmic expression of tumor cells.Positive: scores 2 and 3. (C) score 2: ≤50% expression of tumor cell membranes; (D) score 3: \>50% expression of tumor cell membranes.Figure 6Figure 7PTEN expression. Negative: score 0. (A) score 0: absent expression of tumor cells.Low expression: scores 1--4. (B) score 1: the extent: 20%; the intensity: "+"; (C) score 2: the extent: 50%; the intensity: "+"; (D) score 4: the extent: 60%; the intensity: "++"High expression: scores 6--9. (E) score 6: the extent:90%; the intensity: "++";(F) score 9: the extent: 100%; the intensity: "+++".Figure 7Table 3The Analysis of the Associations Between Pulmonary NETs Subgroups and Immunoprofile.Table 3NE-Related MarkersCarcinoidLCNECSCLCAll 3 TypesCarcinoid vs. LCNECLCNEC vs. SCLCLow to Intermediate vs. High GradeNSCLC vs. SCLC(n = 23)(n = 59)(n = 35)*P* value*P* value*P* value*P* value*P* valuep53 Negative151910.**009**.**006**.712.**002**.187 Positive84025CD117 Negative233618.**000**.**000**.363.**000**.**032** Positive02317SSR2A Negative83924.**017**.**010**.806.**005**.254 Positive152011SSR5 Negative165535.**000**.**005**.115.**000**.**023** Positive740**PTEN** Negative22216.**031**.**037**.331.**012**.105 Low expression230 High expression193419[^4]

Then, in the high-grade subgroup, we found that p53 and CD117 expression was up-regulated, while SSR2A/SSR5 and PTEN expression were down-regulated significantly, compared with the low- to intermediate-grade subgroup (p53-positive, 69.1% vs. 34.8%, *P* = .002; CD117-positive, 42.6% vs. 0%, *P* = .000; SSR2A-positive, 33.0% vs. 65.2%, P = .005; SSR5-positive, 4.3% vs. 30.4%, P = .000; PTEN-cytoplasm, 56.4% vs. 82.6%, *P* = .012). In the comparison between NSCLC and SCLC, we found that only SSR5 expression was down-regulated, while CD117 expression was up-regulated significantly (SSR5-positive, 13.4% vs. 0%, *P* = .023; CD117-positive, 28.0% vs. 48.6%, *P* = .021), and the other markers expression showed no significant difference.

Discussion {#s0050}
==========

The neuroendocrine carcinoma of the pulmonary has unique clinical and pathological feature. It is known to all that the high-grade pulmonary NETs (LCNEC and SCLC) suffered poorer prognosis than the low- to intermediate-grade NETs (TC and AC) [@bb0090]. The detailed molecular mechanisms of these biological and prognostic characteristics still remained unknown. In this study, we focused on clinical features, prognosis and immunoprofiles to analyze the difference between each subgroup and explored whether LCNEC shares some similarity with SCLC.

In the analysis of clinical features, we arrived at a conclusion that LCNEC patients, characteristic of old age, more males than females, and advanced stage, shared similarity with SCLC patients, rather than carcinoid patients. Moreover, when we re-classified patients into the low- to intermediate-grade subgroups and the high-grade subgroups, the same characteristics also could be revealed in the high-grade subgroups compared with the low- to intermediate-grade subgroups. However, when patients were re-classified into NSCLC subgroups and SCLC subgroups, these characteristics showed no significant statistical difference. Rekhtman reported that carcinoid occur in younger patients (mean age, 45--50 years), while the high-grade pulmonary NETs occur predominantly in older patients (mean age, 65 years). Furthermore, the high-grade pulmonary NETs patients are more frequent male [@bb0095]. Our results were consistent with the previous data. For the reason that the high-grade pulmonary NETs show high aggressive biological behavior [@bb0100], these patients might be prone to reaching advanced stage when being diagnosed. Therefore, the statistical analysis indicated that the clinical characteristics of LCNEC were much more similar to SCLC, than to carcinoid.

To analyze the prognostic difference between each subtype of pulmonary NETs, we applied Kaplan--Meier estimator and found that 5-year OS for the carcinoids, LCNECs, and SCLCs were 70.0%, 59.1%, and 32.1%, respectively (*P* = .036). As reported, carcinoid patients have the best prognosis (5-year survival ≥60%). LCNEC was considered a broad range of survival (15%--57%), in which the different treatment approaches and inclusion criteria might result [@bb0105]. The controversy in LCNEC survival also indicated the unknown of its exact biological features and targeted treatments. The most aggressive subtype of pulmonary NETs is SCLC, whose 5-year survival was almost 10--20% [@bb0110]. According to this study, the survival data was in accordance to the previous records. The fact that 5-year survival of LCNEC and SCLC was a little higher than the previous records might be ascribed to the limitation of the inclusion of patients who mostly received radical resection surgery in this study, which means these patients were almost at limited-stage. The patients in extensive-stage who lost operation opportunity might have suffered even poorer prognosis. The survival curve of carcinoid and SCLC in this study occupied the either end of the lifetime span and LCNEC was situated between these two subtypes. Although it is hard to define which end LCNEC was much closer to, the tendency would gradually be revealed with further exploration in-depth in future. Moreover, LCNEC patients were mostly advised to receive the chemotherapy regimen for NSCLC, which were different from the distinctive regimen for SCLC. Therefore, the post-operative chemotherapy was not taken into account in this study.

The p53 protein, as a tumor suppressor, plays a crucial role in the cell cycle regulation. Wild-type p53 inhibits tumor progression through the induction of cell cycle arrest and apoptosis [@bb0115], [@bb0120]. Brian and colleagues demonstrated that p53 was overexpressed in SCLC [@bb0030]. The similar results were also demonstrated in Şahan and colleagues\' study in gastrointestinal and pancreatic neuroendocrine tumors [@bb0040]. Besides p53, the product of the c-kit gene, CD117 was frequently expressed in gastrointestinal stromal tumors [@bb0125]. In NETs, CD117 was also found up-regulated in the high-grade NETs, such as Merkel cell carcinoma [@bb0130], [@bb0135]. Araki and colleagues demonstrated that CD117 was overexpressed in 55% of the LCNEC and 46% of the SCLC tumor cells [@bb0140]. Pelosi and colleagues also analyzed CD117 expression difference among carcinoid, LCNEC and SCLC and found that CD117 was positive-membrane stained in 77% LCNECs, 67% SCLCs and 7% carcinoids, and positive cytoplasm-stained in 44% LCNEC, 70% SCLC 5% carcinoids [@bb0145]. These results indicated that CD117 was much more frequently over-expressed in the high-grade pulmonary NETs than the low- to intermediate-grade ones, which was in accordance with our data.

Somatostatin could inhibit several digestive fluid secretion and somatostatin receptors showed shifted expression in gastrointestinal NETs [@bb0150], [@bb0155]. The somatostatin receptors family includes SSR1 to SSR5, among which SSR2A and SSR5 were applied most frequently according to somatostatin analogue treatment [@bb0080], [@bb0160]. Tsuta and colleagues demonstrated that SSR1, 2A, 2B, 3 and 4 have a tendency toward decreased expression in well to poorly differentiated pulmonary NETs [@bb0165]. However, Kaemmerer and colleagues applied IHC and qRT-PCR in pulmonary NETs and revealed that SSR1 and 5 expression level gradually decreased toward the poorly differentiated tumor subgroups, while SSR2A was present almost the same among each subgroups [@bb0170]. Our data was consistent with Tsuta\'s results. The conflicts between our data and previous studies might result from different scoring standard, different antibodies and limited sample size. Further deeper investigation would be required to reveal the precise mechanism behind the data. Strikingly, our data showed that CD117 was entirely negative in pulmonary carcinoids and SSR5 was also totally negative in SCLC, which might be a good way to distinguish the types of pulmonary NETs. Definitely, the sample size needs to be enlarged to prove these results.

PTEN is another frequent mutated tumor suppressor, which serves as the regulator of the phosphoinositide 3-kinase (PI3K)/Akt/ mTOR and insulin signaling pathway [@bb0175]. Collaud and colleagues revealed that, compared with the carcinoids, the high-grade pulmonary NETs tumors presented a stronger loss of PTEN [@bb0055]. Wada and colleagues analyzed the PTEN expression in the NETs of multiple organs and found that PTEN immunoreactivity levels were significantly lower in the high-grade NETs subgroup, while p53 expression were significantly higher in the high-grade NETs subgroup, which was entirely consistent with our results in pulmonary NETs [@bb0050]. Our data also revealed that, with the elevation of differentiation grade, p53 expression level gradually increased, but PTEN expression level gradually decreased ([Table 3](#t0015){ref-type="table"}). Therefore, considering the expressional difference of p53, CD117, SSR2A, SSR5 and PTEN in each pulmonary NETs subgroup, we speculated that LCNEC shared much more similarity with SCLC, than carcinoid, in immunoprofiles, which also indicated platinum, Imatinib or mTOR inhibitor treatment might be potential therapy for LCNEC.

To conclude, through the analysis of clinical features, overall survival, and immunoprofile between each type of pulmonary NETs, LCNECs shared more similarity with SCLC, rather than carcinoid, which might guide novel therapy for [pulmonary](http://cn.bing.com/dict/search?q=Pulmonary&FORM=BDVSP6&mkt=zh-cn){#ir0005} NETs.
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